Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000665303 | SCV000789397 | uncertain significance | Glycine encephalopathy | 2017-01-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000665303 | SCV000962919 | uncertain significance | Glycine encephalopathy | 2022-11-01 | criteria provided, single submitter | clinical testing | This variant, c.1484_1489del, results in the deletion of 2 amino acid(s) of the GLDC protein (p.Glu495_Leu496del), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (rs778109389, gnomAD 0.005%). This variant has not been reported in the literature in individuals affected with GLDC-related conditions. ClinVar contains an entry for this variant (Variation ID: 550535). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001584531 | SCV001821120 | uncertain significance | not provided | 2024-12-16 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In-frame deletion of 2 amino acids in a non-repeat region; In silico analysis supports a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV000665303 | SCV002777650 | uncertain significance | Glycine encephalopathy | 2022-05-17 | criteria provided, single submitter | clinical testing | |
Genomic Medicine Center of Excellence, |
RCV003989575 | SCV004806159 | uncertain significance | Glycine encephalopathy 1 | 2024-03-25 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001584531 | SCV005196304 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
3billion | RCV003989575 | SCV005328804 | likely benign | Glycine encephalopathy 1 | 2024-09-20 | criteria provided, single submitter | clinical testing | The homozygous variant was found in patients diagnosed with another variant in a different gene, with no symptoms related to the gene containing the homozygous variant. |
Athena Diagnostics | RCV001584531 | SCV005620670 | uncertain significance | not provided | 2024-10-16 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000665303 | SCV001462764 | uncertain significance | Glycine encephalopathy | 2020-01-17 | no assertion criteria provided | clinical testing |